NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).
We are looking at some of the greatest attacks on modern medicine in over a century. The spread of deadly Superbugs that are so aggressive the strongest antibiotics are becoming powerless against them. Antibiotics are beginning to fail as bacteria fight back and adapt.
We believe that Nano Medicines are the future of antibiotics. Our NanoAntibiotics are exciting in that they are being designed to kill the bacteria with a different approach than what presently exists.
Multidrug resistance efflux pumps have become broadly as an important component of resistance in both gram-negative and gram-positive bacteria. Some bacterial pumps are selective for one substrate or transport antibiotics of different classes, conferring the multiple drug resistance. Efflux pump inhibitors are promising agent, as they should restore the activity of standard antibiotics. The efflux pump inhibitor-antibiotic combination has ability to increase the intracellular concentration of antibiotics that are expelled by efflux pump, decrease the bacterial resistance to antibiotics.
Our approach to combat the problem with the effective antibiotic against the multiple drug resistant strain of gram-negative and gram-positive bacteria is like a double edge sword. We are currently developing the effective nano efflux pump inhibitor as well as new class of super antibiotics. Our nano efflux pump inhibitor is being developed to act in synergy with our new class of nanoantibiotics to enhance their efficacy in most difficult to treat Superbugs.
To date, no inhibitors of bacterial efflux pumps have been licensed for use in treatment of bacterial infection in human or veterinary settings. Our efflux pump inhibitor compounds are made of high purified materials with high inhibitory efficacy and no toxic effects on mammal cells.
Bacterial Efflux Pumps:
Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.